Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial - Weber, J S; D'Angelo, S P; Minor, D (Lancet Oncol, 2015)